CLIA Kit for Tumor Protein p53 (TP53)Homo sapiens (Human)Sandwich CLIA

p53; LFS1; TRP53; Li-Fraumeni Syndrome; Cellular tumor antigen p53; Antigen NY-CO-13; Phosphoprotein p53; Tumor suppressor p53

  • Product No.SCA928Hu
  • Organism SpeciesHomo sapiens (Human)Same name, Different species.
  • Sample TypeSerum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
  • Test MethodDouble-antibody Sandwich
  • Assay Length2h, 40min
  • Detection Range78.12-20000pg/mL
  • SensitivityThe minimum detectable dose of this kit is typically less than 9.5pg/mL.
  • Specificity This assay has high sensitivity and excellent specificity for detection of Tumor Protein p53 (TP53).
    No significant cross-reactivity or interference between Tumor Protein p53 (TP53) and analogues was observed.
  • ApplicationsChemiluminescent immunoassay for Antigen Detection
  • DownloadInstruction Manual
  • Format48T96T96T*596T*1096T*100
  • FOBUS$ 588US$ 840US$ 3780US$ 7140US$ 58800
  • CLIA Kit for Tumor Protein p53 (TP53)Package and Components
  • CLIA Kit for Tumor Protein p53 (TP53)Package and Components
  • CLIA Kit for Tumor Protein p53 (TP53)Results demonstration
  • SCA928Hu.jpgTypical Standard Curve
  • CertificateISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Tumor Protein p53 (TP53) and the recovery rates were calculated by comparing the measured value to the expected amount of Tumor Protein p53 (TP53) in samples.

MatrixRecovery range (%)Average(%)
serum(n=5)90-10493
EDTA plasma(n=5)96-105101
heparin plasma(n=5)90-10294

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Tumor Protein p53 (TP53) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Tumor Protein p53 (TP53) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Tumor Protein p53 (TP53) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample1:21:41:81:16
serum(n=5)80-92%83-102%85-99%80-98%
EDTA plasma(n=5)96-104%86-101%86-102%78-93%
heparin plasma(n=5)90-97%91-98%88-99%93-101%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

ReagentsQuantityReagentsQuantity
Pre-coated, ready to use 96-well strip plate1Plate sealer for 96 wells4
Standard2Standard Diluent1×20mL
Detection Reagent A1×120µLAssay Diluent A1×12mL
Detection Reagent B1×120µLAssay Diluent B1×12mL
Substrate A1×10mLSubstrate B1×2mL
Wash Buffer (30 × concentrate)1×20mLInstruction manual1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Tumor Protein p53 (TP53)

Test principle

The microtiter plate provided in this kit has been pre-coated with an antigen. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated secondary antibody. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Tumor Protein p53 (TP53) level in the sample or standard.

Reference

  • Anticancer ResearchAnalysis of p53 and miRNA expression after irradiation of glioblastoma cell linesPubMed: 23155233
  • Microscopy Research and TechniqueTherapeutic role of curcumin in oxidative DNA damage caused by formaldehydePubMed: 25761397
  • J Nutr BiochemSupplementation with Selenium yeast on the prooxidant–antioxidant activities and anti-tumor effects in breast tumor xenograft-bearing micePubMed: 26344777